European Psychiatry (Apr 2024)

Factors influencing stigma in bipolar disorder type I

  • A. Adouni,
  • Y. Zgueb,
  • I. Bouguerra,
  • F. Ben Othman,
  • R. Jomli

DOI
https://doi.org/10.1192/j.eurpsy.2024.887
Journal volume & issue
Vol. 67
pp. S428 – S428

Abstract

Read online

Introduction Given the recurrence of mood episodes, with their negative repercussions such as high suicidal risk, significant cognitive decline and the persistence of residual signs with a negative impact on the patient’s family, social and professional functioning, Bipolar Disorder is a mental disorder with a significant social stigma. Objectives Identify the socio-demographic and clinical factors that may influence the experience of stigma in bipolar disorder type I Methods We conducted a cross-sectional, comparative study over a six-month period at the aftercare unit of Razi Hospital’s psychiatric ward “A”, including patients treated for TB I according to DSM 5 criteria and stable on treatment. The study was conducted in two stages: first, sociodemographic and clinical characteristics were collected using a pre-established form. The DISCUS scale, validated in Arabic, was then administered. Results We included 100 patients (60 men and 40 women) with a mean age of 43.55 years. The median DISCUS stigma score was 6 (0-19). The mean value of the DISCUS scale was high for patients of urban origin (p=0.042), with a low socioeconomic level (p=0.001), and poor family dynamics (p<0.001). The presence of a comorbid personality disorder was significantly associated with stigma (p=0.006). The DISCUS scale was positively associated with the number of years of follow-up, the number of hospitalizations, the number of manic episodes, the number of depressive episodes and the number of episodes with psychotic or melancholic features. Conclusions This stigma can have a negative impact on patients’ quality of life in a whole range of ways, including limiting their opportunities for education, employment and housing. Intensive therapeutic interventions should be considered for vulnerable patients to limit the consequences. Disclosure of Interest None Declared